Bridging the Gaps in Lung Cancer: 6 Month Update Winter Lung Cancer Conference 2025 - Episode 11
The Recent Updates in the Management Advanced NSCLC with HER2 or NRG1 Alterations
Panelists discuss how emerging data on novel HER2-targeted agents, including Beamion LUNG-1 (zongertinib) and SOHO-1 (BAY 2927088), show promise for advanced non–small cell lung cancer (NSCLC). Additionally, the eNRGy trial and FDA approval of zenocutuzumab for NRG1 fusion–positive non–small cell lung cancer (NSCLC) offers new treatment avenues. Patient selection will depend on genetic profiling and treatment efficacy.
Video Player is loading.
Video content above is prompted by the following:
- What are your thoughts on the emerging data surrounding novel HER2-targeted agents, and how may they impact the future treatment landscape for NSCLC?
- Beamion LUNG-1 (zongertinib): Ruiter G, et al. WCLC 2024. Abs PL04.04
- SOHO-1 (BAY 2927088): Le X, et al. WCLC 2024. Abs PL04.03
- Briefly comment on the eNRGy trial andFDA approval (December 2024) ofzenocutuzumab for advanced, unresectable, or metastatic NSCLC harboring an NRG1 gene fusion. (Schram AM, et al. ESMO 2023. Abs 1315MO; FDA.gov, FDA approves zenocutuzumab for NSCLC)
- How might you incorporate this novel therapy into your clinical practice, and what factors guide your patient selection?
